News
Combined clinical-stage company benefits from a strong pipeline: MOv18 IgE, an anti-Folate Receptorα IgE antibody, currently in a Phase Ib Proof of Concept trial in platinum-resistant ovarian cancer.
Combined clinical-stage company benefits from a strong pipeline: MOv18 IgE, an anti-Folate Receptorα IgE antibody, currently in a Phase Ib Proof of Concept trial in platinum-resistant ovarian cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback